Importance: Surgical aortic valve replacement (SAVR) has increased risk for patients with aortic stenosis (AS) and a history of coronary artery bypass graft (CABG) surgery. Transcatheter aortic valve replacement (TAVR) may be an alternative. Objective: To compare TAVR with SAVR outcomes in patients at intermediate operative risk with prior CABG surgery. Design, Setting, and Participants: In this post hoc analysis of the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) noninferiority randomized clinical trial, patients with severe, symptomatic AS at intermediate operative risk were enrolled from 87 centers across the United States, Europe, and Canada from June 2012 to June 2016 and followed-up with up to July 2017. Those with a history of CABG surgery were considered for analysis. Data were analyzed from September to December 2017. Interventions: A total of 1746 patients were enrolled and randomized 1:1 to self-expanding TAVR or SAVR. An implant was attempted in 1660 patients, of whom 273 had prior CABG surgery, including 136 who underwent attempted TAVR and 137 who underwent attempted SAVR. Main Outcomes and Measures: The primary outcome was all-cause mortality or disabling stroke at 1-year follow-up. Efficacy outcomes included quality of life, measured using the Kansas City Cardiomyopathy Questionnaire at 30 days, 6 months, and 1 year, and distance walked in 6 minutes, measured using the 6-minute walk test at 30 days and 1 year. Results: Of the 136 patients in the TAVR cohort, 111 (81.6%) were male, and the mean (SD) age was 76.9 (6.5) years; of the 137 in the SAVR cohort, 117 (85.4%) were male, and the mean (SD) age was 76.6 (6.5) years. The mean (SD) Society of Thoracic Surgeons Predicted Risk of Mortality score was 5.0% (1.6%) in the TAVR cohort and 5.2% (1.7%) in the SAVR cohort. All-cause mortality or disabling stroke at 1-year follow-up was 8.9% (95% CI, 5.2-15.2) in the TAVR cohort and 6.7% (95% CI, 3.5-12.8) in the SAVR cohort (log-rank P = .53). Compared with patients receiving SAVR, the mean (SD) Kansas City Cardiomyopathy Questionnaire summary score was significantly better among patients receiving TAVR at 30 days (81.4 [19.2] vs 69.7 [22.6]; P < .001); treatments were similar at 1 year (85.7 [14.6] vs 82.8 [18.4]; P = .19). Compared with patients in the SAVR cohort, those in the TAVR cohort showed greater mean (SD) improvement in distance walked at 1 year (48.3 [120.6] m vs 16.8 [88.7] m; P = .04). Conclusions and Relevance: Both TAVR and SAVR were safe for intermediate-risk patients with AS and prior CABG surgery. The transcatheter approach facilitated faster improvement in quality of life and better exercise capacity at 1-year follow-up. Trial Registration: ClinicalTrials.gov identifier: NCT01586910.
RCT Entities:
Importance: Surgical aortic valve replacement (SAVR) has increased risk for patients with aortic stenosis (AS) and a history of coronary artery bypass graft (CABG) surgery. Transcatheter aortic valve replacement (TAVR) may be an alternative. Objective: To compare TAVR with SAVR outcomes in patients at intermediate operative risk with prior CABG surgery. Design, Setting, and Participants: In this post hoc analysis of the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) noninferiority randomized clinical trial, patients with severe, symptomatic AS at intermediate operative risk were enrolled from 87 centers across the United States, Europe, and Canada from June 2012 to June 2016 and followed-up with up to July 2017. Those with a history of CABG surgery were considered for analysis. Data were analyzed from September to December 2017. Interventions: A total of 1746 patients were enrolled and randomized 1:1 to self-expanding TAVR or SAVR. An implant was attempted in 1660 patients, of whom 273 had prior CABG surgery, including 136 who underwent attempted TAVR and 137 who underwent attempted SAVR. Main Outcomes and Measures: The primary outcome was all-cause mortality or disabling stroke at 1-year follow-up. Efficacy outcomes included quality of life, measured using the Kansas City Cardiomyopathy Questionnaire at 30 days, 6 months, and 1 year, and distance walked in 6 minutes, measured using the 6-minute walk test at 30 days and 1 year. Results: Of the 136 patients in the TAVR cohort, 111 (81.6%) were male, and the mean (SD) age was 76.9 (6.5) years; of the 137 in the SAVR cohort, 117 (85.4%) were male, and the mean (SD) age was 76.6 (6.5) years. The mean (SD) Society of Thoracic Surgeons Predicted Risk of Mortality score was 5.0% (1.6%) in the TAVR cohort and 5.2% (1.7%) in the SAVR cohort. All-cause mortality or disabling stroke at 1-year follow-up was 8.9% (95% CI, 5.2-15.2) in the TAVR cohort and 6.7% (95% CI, 3.5-12.8) in the SAVR cohort (log-rank P = .53). Compared with patients receiving SAVR, the mean (SD) Kansas City Cardiomyopathy Questionnaire summary score was significantly better among patients receiving TAVR at 30 days (81.4 [19.2] vs 69.7 [22.6]; P < .001); treatments were similar at 1 year (85.7 [14.6] vs 82.8 [18.4]; P = .19). Compared with patients in the SAVR cohort, those in the TAVR cohort showed greater mean (SD) improvement in distance walked at 1 year (48.3 [120.6] m vs 16.8 [88.7] m; P = .04). Conclusions and Relevance: Both TAVR and SAVR were safe for intermediate-risk patients with AS and prior CABG surgery. The transcatheter approach facilitated faster improvement in quality of life and better exercise capacity at 1-year follow-up. Trial Registration: ClinicalTrials.gov identifier: NCT01586910.
Authors: Suzanne V Arnold; Matthew R Reynolds; Kaijun Wang; Elizabeth A Magnuson; Suzanne J Baron; Khaja M Chinnakondepalli; Michael J Reardon; Peter N Tadros; George L Zorn; Brij Maini; Mubashir A Mumtaz; John M Brown; Robert M Kipperman; David H Adams; Jeffrey J Popma; David J Cohen Journal: JACC Cardiovasc Interv Date: 2015-08-17 Impact factor: 11.195
Authors: Hunaid A Vohra; Dimitrios Pousios; Robert N Whistance; Marcus P Haw; Clifford W Barlow; Sunil K Ohri; Steve A Livesey; Geoffrey M K Tsang Journal: Eur J Cardiothorac Surg Date: 2011-12-26 Impact factor: 4.191
Authors: John V Conte; Thomas G Gleason; Jon R Resar; David H Adams; G Michael Deeb; Jeffrey J Popma; G Chad Hughes; George L Zorn; Michael J Reardon Journal: Ann Thorac Surg Date: 2015-10-01 Impact factor: 4.330
Authors: Fausto Biancari; Francesco Onorati; Giovanni Mariscalco; Marisa De Feo; Antonio Messina; Giuseppe Santarpino; Francesco Santini; Cesare Beghi; Ester Della Ratta; Giovanni Troise; Theodor Fischlein; Giancarlo Passerone; Tatu Juvonen; Alessandro Mazzucco; Jouni Heikkinen; Giuseppe Faggian Journal: J Card Surg Date: 2014-05-26 Impact factor: 1.620
Authors: Michael J Reardon; Nicolas M Van Mieghem; Jeffrey J Popma; Neal S Kleiman; Lars Søndergaard; Mubashir Mumtaz; David H Adams; G Michael Deeb; Brijeshwar Maini; Hemal Gada; Stanley Chetcuti; Thomas Gleason; John Heiser; Rüdiger Lange; William Merhi; Jae K Oh; Peter S Olsen; Nicolo Piazza; Mathew Williams; Stephan Windecker; Steven J Yakubov; Eberhard Grube; Raj Makkar; Joon S Lee; John Conte; Eric Vang; Hang Nguyen; Yanping Chang; Andrew S Mugglin; Patrick W J C Serruys; Arie P Kappetein Journal: N Engl J Med Date: 2017-03-17 Impact factor: 91.245
Authors: Kevin L Greason; Verghese Mathew; Rakesh M Suri; David R Holmes; Charanjit S Rihal; Tom McAndrew; Ke Xu; Michael Mack; John G Webb; Augusto Pichard; Mathew Williams; Martin B Leon; Lars Svensson; Vinod Thourani; Craig R Smith Journal: Ann Thorac Surg Date: 2014-06-02 Impact factor: 4.330
Authors: Tanush Gupta; Sahil Khera; Dhaval Kolte; Kashish Goel; Ankur Kalra; Pedro A Villablanca; Herbert D Aronow; J Dawn Abbott; Gregg C Fonarow; Cynthia C Taub; Neal S Kleiman; Giora Weisz; Ignacio Inglessis; Sammy Elmariah; Charanjit S Rihal; Mario J Garcia; Deepak L Bhatt Journal: Circ Cardiovasc Interv Date: 2018-04 Impact factor: 6.546
Authors: Alina Zubarevich; Marcin Szczechowicz; Lukman Amanov; Arian Arjomandi Rad; Anja Osswald; Saeed Torabi; Arjang Ruhparwar; Alexander Weymann Journal: Life (Basel) Date: 2022-06-29